Actionability and scope should determine the extent of counselling for presymptomatic genetic testing

Bettina Zimmermann; Georg Starke; David Shaw; Bernice Elger; Insa Koné

doi:10.4414/smw.2020.20274

Viewpoint

Vol. 150 No. 2728 (2020)

Actionability and scope should determine the extent of counselling for presymptomatic genetic testing

Bettina Zimmermann⁺⁻
Georg Starke⁺⁻
David Shaw⁺⁻
Bernice Elger⁺⁻
Insa Koné⁺⁻

DOI: https://doi.org/10.4414/smw.2020.20274
Cite this as:: Swiss Med Wkly. 2020;150:w20274
Published: 29.06.2020

References

Rössler F, Lemke JR. Legislation on Genetic Testing in Different Countries. In: Kiess W, Bornehag C-G, Gennings C, editors. Pediatric Epidemiology. Pediatric and Adolescent Medicine. Basel: Karger; 2017. p. 30–40.
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al.; US Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(7):652–65. doi:.https://doi.org/10.1001/jama.2019.10987
Skirton H, Goldsmith L, Jackson L, Tibben A. Quality in genetic counselling for presymptomatic testing--clinical guidelines for practice across the range of genetic conditions. Eur J Hum Genet. 2013;21(3):256–60. doi:.https://doi.org/10.1038/ejhg.2012.174
Garrison NA, Brothers KB, Goldenberg AJ, Lynch JA. Genomic Contextualism: Shifting the Rhetoric of Genetic Exceptionalism. Am J Bioeth. 2019;19(1):51–63. doi:.https://doi.org/10.1080/15265161.2018.1544304
Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes. 2000;49(12):2201–7. doi:.https://doi.org/10.2337/diabetes.49.12.2201
Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237(4):474–82. doi:.https://doi.org/10.1097/01.SLA.0000059969.64262.87
Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30. doi:.https://doi.org/10.1086/375033
Ligthart S, van Herpt TTW, Leening MJG, Kavousi M, Hofman A, Stricker BHC, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(1):44–51. doi:.https://doi.org/10.1016/S2213-8587(15)00362-9
Guttmacher AE, Collins FS, Carmona RH. The family history--more important than ever. N Engl J Med. 2004;351(22):2333–6. doi:.https://doi.org/10.1056/NEJMsb042979
Brock D. Ethical Issues in the Use of Cost Effectiveness Analysis for the Prioritization of Health Resources. In: Khushf G, editor. Handbook of Bioethics. Philosophy and Medicine. Dordrecht: Kluwer Academic Publishers; 2004. p. 353–80.

Publication image

How to Cite

1.

Zimmermann B, Starke G, Shaw D, Elger B, Koné I. Actionability and scope should determine the extent of counselling for presymptomatic genetic testing. Swiss Med Wkly [Internet]. 2020 Jun. 29 [cited 2024 Apr. 20];150(2728):w20274. Available from: https://smw.ch/index.php/smw/article/view/2821

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Andrea Martani, David Shaw, Bernice Simone Elger, Stay fit or get bit – ethical issues in sharing health data with insurers’ apps , Swiss Medical Weekly: Vol. 149 No. 2526 (2019)
Andrea Martani, Philipp Egli, Michael Widmer, Bernice Elger, Data protection and biomedical research in Switzerland: setting the record straight , Swiss Medical Weekly: Vol. 150 No. 3536 (2020)
Verina Wild, Fourie Carina, Regula Frouzakis, Caroline Clarinval, Margrit Fässler, Bernice Elger, Thomas Gächter, Agnes Leu, Rebecca Spirig, Michael Kleinknecht, Dragana Radovanovic, Corine Mouton Dorey, Bernard Burnand, John-Paul Vader, Jean-Marie Januel, Nikola Biller-Andorno, The IDoC group, Assessing the impact of DRGs on patient care and professional practice in Switzerland (IDoC) – a potential model for monitoring and evaluating healthcare reform , Swiss Medical Weekly: Vol. 145 No. 0708 (2015)
Sophie Haesen, David Shaw, Directing citizens to create advance directives , Swiss Medical Weekly: Vol. 148 No. 1920 (2018)
Stuart McLennan, Roxanne Maritz, David Shaw, Bernice Elger, The inconsistent ethical oversight of healthcare quality data in Switzerland , Swiss Medical Weekly: Vol. 148 No. 2728 (2018)
Ina Otte, Corinna Jung, Bernice Elger, Klaus Bally, Advance directives and the impact of timing , Swiss Medical Weekly: Vol. 144 No. 3940 (2014)
Insa Koné, Bettina Zimmermann, Tenzin Wangmo, Silvia Richner, Markus Weber, Bernice Elger, Hospital discharge of patients with ongoing care needs: a cross-sectional study using data from a city hospital under SwissDRG , Swiss Medical Weekly: Vol. 148 No. 0304 (2018)
Stuart McLennan, David Shaw, Agnes Leu, Bernice Elger, Professional liability insurance and medical error disclosure , Swiss Medical Weekly: Vol. 145 No. 2728 (2015)
Stuart McLennan, Sabrina Engel, Katharina Ruhe, Agnes Leu, David Schwappach, Bernice Elger, Implementation status of error disclosure standards reported by Swiss hospitals , Swiss Medical Weekly: Vol. 143 No. 2728 (2013)
Julius Weiss, David Shaw, Roger Schober, Viviana Abati, Franz F. Immer, Swiss Medical Weekly, Attitudes towards organ donation and relation to wish to donate posthumously , Swiss Medical Weekly: Vol. 147 No. 0506 (2017)

1 2 > >>

[1] Rössler F, Lemke JR. Legislation on Genetic Testing in Different Countries. In: Kiess W, Bornehag C-G, Gennings C, editors. Pediatric Epidemiology. Pediatric and Adolescent Medicine. Basel: Karger; 2017. p. 30–40.

[2] Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al.; US Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(7):652–65. doi:.https://doi.org/10.1001/jama.2019.10987

[3] Skirton H, Goldsmith L, Jackson L, Tibben A. Quality in genetic counselling for presymptomatic testing--clinical guidelines for practice across the range of genetic conditions. Eur J Hum Genet. 2013;21(3):256–60. doi:.https://doi.org/10.1038/ejhg.2012.174

[4] Garrison NA, Brothers KB, Goldenberg AJ, Lynch JA. Genomic Contextualism: Shifting the Rhetoric of Genetic Exceptionalism. Am J Bioeth. 2019;19(1):51–63. doi:.https://doi.org/10.1080/15265161.2018.1544304

[5] Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes. 2000;49(12):2201–7. doi:.https://doi.org/10.2337/diabetes.49.12.2201

[6] Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237(4):474–82. doi:.https://doi.org/10.1097/01.SLA.0000059969.64262.87

[7] Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30. doi:.https://doi.org/10.1086/375033

[8] Ligthart S, van Herpt TTW, Leening MJG, Kavousi M, Hofman A, Stricker BHC, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(1):44–51. doi:.https://doi.org/10.1016/S2213-8587(15)00362-9

[9] Guttmacher AE, Collins FS, Carmona RH. The family history--more important than ever. N Engl J Med. 2004;351(22):2333–6. doi:.https://doi.org/10.1056/NEJMsb042979

[10] Brock D. Ethical Issues in the Use of Cost Effectiveness Analysis for the Prioritization of Health Resources. In: Khushf G, editor. Handbook of Bioethics. Philosophy and Medicine. Dordrecht: Kluwer Academic Publishers; 2004. p. 353–80.